Liu JW, Tang Y, Shen Y, Zhong XY. Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells.
World J Gastroenterol 2003;
9:65-8. [PMID:
12508353 PMCID:
PMC4728251 DOI:
10.3748/wjg.v9.i1.65]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To illustrate the possible role of cell differential agent-II (CDA-II) in the apoptosis of hepatoma cells induced by arsenic trioxide (As2O3).
METHODS: Hepatoma cell lines BEL-7402 and HepG2 were treated with As2O3 together with CDA-II. Cell surviving fraction was determined by MTT assay; morphological changes were observed by immunofluorescence staining of Hoechst 33258; and cell cycle and the apoptosis index were determined by flow cytometry (FCM).
RESULTS: Cytotoxity of CDA-II was low. Nevertheless, CDA-II could strongly potentiate arsenic trioxide-induced apoptosis. At 1.0 g/L CDA-II, IC50 of As2O3 in hepatoma cell lines was reduced from 5.0 µmol/L to 1.0 µmol/L (P < 0.01). The potentiation of apoptosis was dependent on the dosage of CDA-II. FCM indicated that in hepatoma, cell growth was inhibited by CDA-II at lower concentrations (< 2.0 g/L) primarily by arresting at S and G2 phase, and at higher concentrations (> 2.0 g/L) apoptotic cell and cell cycle arresting at G1 phase increased proportionally. The combination of two drugs led to much higher apoptotic rates, as compared with the either drug used alone.
CONCLUSION: CDA-II can strongly potentiate As2O3-induced apoptosis in hepatoma cells, and two drugs can produce a significant synergic effect.
Collapse